Samuele Calabro

Samuele Calabro is a Principal Scientist at Roche, where they focus on immunology research. They previously served as a Senior Scientist at Roche and undertook postdoctoral research at Yale University School of Medicine, studying immune responses to red blood cell transfusions. Samuele earned their master's degree in Molecular Biology with honors from the University of Siena and completed a Ph.D. at Novartis Vaccines, where they characterized the mechanism of action of the human vaccine adjuvant MF59. Samuele also worked as a visiting scholar at Boston University School of Medicine, investigating cell types involved in specific immune activities.